|
gptkbp:instanceOf
|
alkaloid
opioid
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:antidote
|
gptkb:naloxone
|
|
gptkbp:ATCCode
|
N02AA01
|
|
gptkbp:brand
|
gptkb:Astramorph
gptkb:Duramorph
gptkb:Roxanol
gptkb:Sevredol
gptkb:MS_Contin
gptkb:Avinza
gptkb:Kadian
gptkb:Oramorph
|
|
gptkbp:canCauseDependence
|
yes
|
|
gptkbp:canCauseTolerance
|
yes
|
|
gptkbp:CASNumber
|
57-27-2
|
|
gptkbp:chemicalFormula
|
C17H19NO3
|
|
gptkbp:controlledSubstanceSchedule
|
yes
|
|
gptkbp:derivedFrom
|
gptkb:opium_poppy
|
|
gptkbp:discoveredBy
|
gptkb:Friedrich_Sertürner
|
|
gptkbp:discoveredIn
|
1804
|
|
gptkbp:eliminationHalfLife
|
2–3 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:foundIn
|
gptkb:Papaver_somniferum
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Morphine
|
|
gptkbp:IUPACName
|
(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
|
|
gptkbp:legalStatus
|
gptkb:Class_A_(UK)
gptkb:Schedule_II_(US)
Schedule I (Canada)
|
|
gptkbp:marketedAs
|
1827
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:meltingPoint
|
254°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
285.34 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
5288826
CHEMBL44957
DB00295
|
|
gptkbp:riskOfOverdose
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
rectal
epidural
intrathecal
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
itching
drowsiness
respiratory depression
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:UNII
|
76I7G6D29C
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:usedIn
|
myocardial infarction
palliative care
anesthesia
chronic pain
acute pain
cancer pain
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Poppy
gptkb:Opiate
|
|
gptkbp:bfsLayer
|
5
|